The additional natriuretic effect (and resultant osmotic diuresis) of SGLT2 inhibitors could potentially be beneficial in patients with cardiovascular disease, especially those with HF, thereby distinguishing SGLT2-inhibitors from all the other oral anti-diabetic agents. This evidence concerns the gene SLC5A2 and cardiovascular disorder.